Gynecologic Cancer Steering Committee

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

The NCI Gynecologic Cancer Steering Committee (GCSC) was transitioned into a NCI Disease Specific Steering Committee from the Gynecologic Cancer Intergroup in May 2006.

Mission Statement

The GCSC functions to harmonize an efficient, cost-effective, science-driven, and transparent process that will identify and promote the "Best Science" in gynecologic cancer clinical research by addressing the design and prioritization of phase 3 trials and evaluating randomized phase 2 studies. As part of its mission, this GCSC is intent on fostering collaboration with international groups and institutions engaged in conducting trials in gynecologic cancers.

Roster of Gynecologic Cancer Steering Committee (GCSC) members


2015 Gynecologic Cancer Steering Committee Strategic Priorities

Task Forces

  • Cervical Cancer: Alan Covens, M.D., and Don S. Dizon, M.D., Co-chairs
  • Ovarian Cancer: Deborah Armstrong, M.D., and Kunle Odunsi, M.D., Co-chairs
  • Uterine Cancer: Linda R. Duska, M.D., M.P.H., and Martee L. Hensley, M.D., Co-chairs

GCSC Activities

Clinical Trials Planning Meetings (CTPMs)

Lymphadenectomy Working Group – 2012

Clinical Trials

The following are clinical trials that were approved at the concept stage by the Steering Committee:

Trial IDNCT IDTrial Title
GOG-0240 NCT00803062 Phase III Randomized Study of Paclitaxel in Combination With Cisplatin or Topotecan Hydrochloride With Versus Without Bevacizumab in Patients With Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix
GOG-0249 NCT00807768 Phase III Randomized Study of Pelvic Radiotherapy Versus Vaginal Cuff Brachytherapy, Paclitaxel, and Carboplatin in Patients With High-Risk Stage I or II Endometrial Carcinoma
GOG-0248 NCT00729586 Phase II Randomized Study of Temsirolimus With or Without Hormonal Therapy Comprising Megestrol Acetate and Tamoxifen Citrate in Patients With Advanced, Persistent, or Recurrent Endometrial Carcinoma
GOG-0238 NCT00492778 Phase II Randomized Study of Pelvic Radiotherapy With Versus Without Cisplatin in Patients With Recurrent Endometrial Cancer
GOG-0213 NCT00565851 Phase III Randomized Study of Adjuvant Chemotherapy Comprising Carboplatin and Paclitaxel With Versus Without Bevacizumab and/or Secondary Cytoreduction Surgery in Patients With Platinum-Sensitive Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
GOG-0258 NCT00942357 A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
GOG-0261 (NCT00954174) Randomized Phase III Trial of Carboplatin plus Paclitaxel versus Ifosfamide plus Taxol in Patients with Advanced, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus
GOG-0252 NCT00951496 Phase III Clinical Trial of Bevacizumab with IV versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
RTOG-0724 NCT00980954 Phase III Randomized Study of Concurrent Chemotherapy and Pelvic RT with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
GOG-0255 NCT00857545 A Randomized Phase III Trial in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer with a Polyvalent Vaccine-KLH Conjugate + QS-21 versus QS-21
GOG-0250 NCT01012297 Randomized Phase IIB Evaluation of Gemcitabine-Docetaxel with or without Bevacizumab for Advanced or Recurrent Uterine Leiomyosarcoma
GOG-0263 NCT01101451 Randomized Clinical Trial for Adjuvant Chemo-radiation in Post-operative Cervical Cancer Patients with Intermediate Risk Factors
GOG-0264 NCT01042522 A Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage Sex Cord-Stromal Tumors of the Ovary
SWOG-S0904 NCT00872989 Randomized Phase II Study of Docetaxel Followed by ZD6474 (Vandetanib) vs. Docetaxel plus ZD6474 in Patients with Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
GOG-0262 NCT01167712 A Randomized Phase III Trial of Every-Three-Weeks versus Dose Dense Weekly Paclitaxel and Carboplatin plus Concurrent Bevacizumab in the Treatment of Primary Suboptimal Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma
GOG-0241 NCT01081262 A Randomized Phase III Evaluation of Capecitabine and Oxaliplatin (Xelox) versus Carboplatin and Paclitaxel in Mucinous Adenocarcinoma of the Ovary

Find all NCI-sponsored clinical trials.

CCCT Contact: Jean M. Lynn, RN, MPH, OCN